Bookmark and Share
BioAssay: AID 588438

Late stage assay provider results from the probe development effort to identify inhibitors of Protein Arginine Deiminase 4 (PAD4): colorimetric biochemical substrate assay to assess potency of compound 1 against PAD1-4

Name: Late stage assay provider results from the probe development effort to identify inhibitors of Protein Arginine Deiminase 4 (PAD4): colorimetric biochemical substrate assay to assess potency of compound 1 against PAD1-4. ..more
_
   
 Tested Compounds
 Tested Compounds
All(1)
 
 
Active(1)
 
 
 Tested Substances
 Tested Substances
All(1)
 
 
Active(1)
 
 
AID: 588438
Data Source: The Scripps Research Institute Molecular Screening Center (PAD1-4_INH_ABS_96_2XIC50_CMPD1)
BioAssay Type: Panel, Confirmatory, Concentration-Response Relationship Observed
Depositor Category: NIH Molecular Libraries Probe Production Network, Assay Provider
Deposit Date: 2011-10-05
Hold-until Date: 2012-09-27
Modify Date: 2012-09-27

Data Table ( Complete ):           View Active Data    View All Data
BioActive Compound: 1
Related Experiments
Show more
AIDNameTypeComment
463073Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4)Screeningdepositor-specified cross reference: Primary screen (PAD4 inhibitors in singlicate, NIH 2K Validation)
463083Summary of the probe development effort to identify inhibitors of Protein Arginine Deiminase 4 (PAD4)Summarydepositor-specified cross reference: Summary (PAD4 inhibitors)
485272Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS)Screeningdepositor-specified cross reference: Primary screen (PAD4 inhibitors in singlicate)
488796Fluorescence polarization-based biochemical high throughput confirmation assay for inhibitors of Protein Arginine Deiminase 4 (PAD4)Screeningdepositor-specified cross reference: Confirmation screen (PAD4 inhibitors in triplicate)
492970Fluorescence-based biochemical dose response assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4)Confirmatorydepositor-specified cross reference: Dose response (PAD5 inhibitors in duplicate)
651627Late stage assay provider results from the probe development effort to identify inhibitors of Protein Arginine Deiminase 4 (PAD4): colorimetric biochemical substrate dialysis assay to assess binding mode of test compounds to PAD4Otherdepositor-specified cross reference
651628Late stage assay provider results from the probe development effort to identify inhibitors of Protein Arginine Deiminase 4 (PAD4): fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) assessment of compound selectivityOtherdepositor-specified cross reference
651861Late stage assay provider results from the probe development effort to identify inhibitors of Protein Arginine Deiminase 4 (PAD4): colorimetric biochemical substrate dialysis assay to assess binding mode of test compounds to PADs 1-3Otherdepositor-specified cross reference
651865Late stage assay provider results from the probe development effort to identify inhibitors of Protein Arginine Deiminase 4 (PAD4): colorimetric biochemical substrate assay to determine rate constants of test compounds for PAD 2 inactivationOtherdepositor-specified cross reference
651866Late stage assay provider results from the probe development effort to identify inhibitors of Protein Arginine Deiminase 4 (PAD4): colorimetric biochemical substrate assay to determine rate constants of test compounds for PAD 3 inactivationOtherdepositor-specified cross reference
651867Late stage assay provider results from the probe development effort to identify inhibitors of Protein Arginine Deiminase 4 (PAD4): colorimetric biochemical substrate assay to determine rate constants of test compounds for PAD 4 inactivationOtherdepositor-specified cross reference
651868Late stage assay provider results from the probe development effort to identify inhibitors of Protein Arginine Deiminase 4 (PAD4): colorimetric biochemical substrate assay to determine rate constants of test compounds for PAD 1 inactivationOtherdepositor-specified cross reference
651887Late stage assay provider results from the probe development effort to identify inhibitors of Protein Arginine Deiminase 4 (PAD4): cell-based absorbance-based assay to assess cytotoxicity of test compoundsConfirmatorydepositor-specified cross reference
588416Late stage assay provider results from the probe development effort to identify inhibitors of Protein Arginine Deiminase 4 (PAD4): colorimetric biochemical substrate assay to assess potency of compound 16 against PAD4Confirmatorysame project related to Summary assay
588417Late stage assay provider results from the probe development effort to identify inhibitors of Protein Arginine Deiminase 4 (PAD4): colorimetric biochemical substrate assay to assess potency of compound 15 against PAD4Confirmatorysame project related to Summary assay
588418Late stage assay provider results from the probe development effort to identify inhibitors of Protein Arginine Deiminase 4 (PAD4): colorimetric biochemical substrate assay to assess potency of compound 13 against PAD4Confirmatorysame project related to Summary assay
588419Late stage assay provider results from the probe development effort to identify inhibitors of Protein Arginine Deiminase 4 (PAD4): colorimetric biochemical substrate assay to assess potency of compound 12 against PAD4Confirmatorysame project related to Summary assay
588420Late stage assay provider results from the probe development effort to identify inhibitors of Protein Arginine Deiminase 4 (PAD4): colorimetric biochemical substrate assay to assess potency of compound 11 against PAD4Confirmatorysame project related to Summary assay
588421Late stage assay provider results from the probe development effort to identify inhibitors of Protein Arginine Deiminase 4 (PAD4): colorimetric biochemical assay to assess potency of compound 6 against PAD4Confirmatorysame project related to Summary assay
588422Late stage assay provider results from the probe development effort to identify inhibitors of Protein Arginine Deiminase 4 (PAD4): colorimetric biochemical assay to assess potency of compound 2 against PAD4Confirmatorysame project related to Summary assay
588423Late stage assay provider results from the probe development effort to identify inhibitors of Protein Arginine Deiminase 4 (PAD4): colorimetric biochemical substrate assay to assess potency of compound 18 against PAD4Confirmatorysame project related to Summary assay
588462Late stage assay provider results from the probe development effort to identify inhibitors of Protein Arginine Deiminase 4 (PAD4): colorimetric biochemical substrate assay to assess potency of streptonigrin against PAD1-3Confirmatorysame project related to Summary assay
588471Late stage assay provider results from the probe development effort to identify inhibitors of Protein Arginine Deiminase 4 (PAD4): colorimetric biochemical substrate assay to assess potency of compound 3 against PAD1-4Confirmatorysame project related to Summary assay
588472Late stage assay provider results from the probe development effort to identify inhibitors of Protein Arginine Deiminase 4 (PAD4): colorimetric biochemical substrate assay to assess potency of compound 14 against PAD1-4Confirmatorysame project related to Summary assay
588484Late stage assay provider results from the probe development effort to identify inhibitors of Protein Arginine Deiminase 4 (PAD4): colorimetric biochemical substrate assay to assess potency of compound 10 against PAD1-4Confirmatorysame project related to Summary assay
588486Late stage assay provider results from the probe development effort to identify inhibitors of Protein Arginine Deiminase 4 (PAD4): colorimetric biochemical substrate assay to assess potency of compound 21 against PAD1-4Confirmatorysame project related to Summary assay
588487Late stage assay provider results from the probe development effort to identify inhibitors of Protein Arginine Deiminase 4 (PAD4): fluorescence-based biochemical gel-based competitive Activity-Based Protein Profiling (ABPP) inhibition by HTS hits of PADs 1-4Othersame project related to Summary assay
588488Late stage assay provider results from the probe development effort to identify inhibitors of Protein Arginine Deiminase 4 (PAD4): colorimetric biochemical substrate assay to assess potency of HTS hits against PAD1-4Othersame project related to Summary assay
588490Late stage assay provider results from the probe development effort to identify inhibitors of Protein Arginine Deiminase 4 (PAD4): colorimetric biochemical substrate assay to assess potency of compound 17 against PAD1-4Confirmatorysame project related to Summary assay
588559Late stage assay provider results from the probe development effort to identify inhibitors of Arginine Deiminase 4 (PAD4): colorimetric biochemical substrate assay to identify inhibitors of PAD4Othersame project related to Summary assay
588560Late stage assay provider results from the probe development effort to identify inhibitors of PAD4: colorimetric biochemical substrate assay to identify inhibitors of PADs 1-4Othersame project related to Summary assay
Description:
Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)
Center Affiliation: The Scripps Research Institute (TSRI)
Assay Provider: Paul Thompson, TSRI (Florida)
Network: Molecular Libraries Probe Production Centers Network (MLPCN)
Grant Proposal Number: R01 GM079357-01
Grant Proposal PI: Paul Thompson
External Assay ID: PAD1-4_INH_ABS_96_2XIC50_CMPD1

Name: Late stage assay provider results from the probe development effort to identify inhibitors of Protein Arginine Deiminase 4 (PAD4): colorimetric biochemical substrate assay to assess potency of compound 1 against PAD1-4.

Description:

Rheumatoid Arthritis (RA) is a chronic and progressive autoimmune disorder that affects about one percent of the US population (1). Existing therapies treat the symptoms of the disease but not the underlying cause, and are associated with numerous side effects (2). The activity of Protein Arginine Deiminase 4 (PAD4), one of four known active PAD isozymes, is increased in RA; where it is thought to generate a subset of antigens that the immune system recognizes as foreign (3). Genetic, serological, and biochemical evidence suggests that dysregulated PAD4, and potentially PAD2, activities play a role in both the onset and progression of RA (1). Cl-amidine, a compound that specifically inactivates PAD4, reduces disease severity and incidence in the collagen-induced model of arthritis (CIA) (unpublished observations). However, because Cl-amidine inhibits all of the PAD isozymes with equipotency, it is unclear whether the observed reduction in disease severity is due to the inhibition of single or multiple PADs. This is particularly relevant because both PAD 2 and 4 are overexpressed in the joints of patients with RA (4). Thus, the identification of PAD selective inhibitors would facilitate the characterization of their individual contributions to the onset and progression of RA and represent a promising novel therapeutic approach for RA.

References:

1. Vossenaar, E.R., et al., PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. Bioessays, 2003. 25(11): p. 1106-18.
2. Smolen, J.S. and G. Steiner, Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov, 2003. 2(6): p. 473-88.
3. Vossenaar, E.R., et al., Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages. Ann Rheum Dis, 2004. 63(4): p. 373-81.
4. Lundberg, K., et al., Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity. Arthritis Res Ther, 2005. 7(3): p. R458-67.

Keywords:

late stage, late stage AID, assay provider, powders, protein arginine deiminase type-1, protein arginine deiminase type-2, protein arginine deiminase type-3, protein arginine deiminase type-4, PAD1, PAD2, PAD3, PAD4, rheumatoid arthritis, RA, collagen-induced model of arthritis, Na-Benzoyl-L-arginine ethyl ester hydrochloride, BAEE, citrulline, absorbance, IC50, Scripps, The Scripps Research Institute Molecular Screening Center, SRIMSC, Molecular Libraries Probe Production Centers Network, MLPCN
Panel Information
Targets
    Data Table(Active)    Data Table(All)Show more
PID§NameSubstancePanel TargetsDescriptionAdditional Information
ActiveInactive
1PAD11protein-arginine deiminase type-1 [Homo sapiens] [gi:122056685]
Taxonomy id: 9606
Gene id: 29943
2PAD21protein-arginine deiminase type-2 [Homo sapiens] [gi:122939159]
Taxonomy id: 9606
Gene id: 11240
3PAD31protein-arginine deiminase type-3 [Homo sapiens] [gi:122939161]
Taxonomy id: 9606
Gene id: 51702
4PAD41protein-arginine deiminase type-4 [Homo sapiens] [gi:216548487]
Taxonomy id: 9606
Gene id: 23569

§ Panel component ID.
Protocol
Assay Overview:
The purpose of this assay is to assess the potency of test compounds for inhibition of PADs 1-4 using a substrate-based assay. In this assay, the target enzyme is pre-incubated with test compound followed by addition of substrate Na-benzoyl-L-arginine ethyl ester HCl (BAEE). The percent activity remaining is determined by measuring the amount of citrulline produced using a standard colorimetric absorbance assay. Test compounds that act as PAD inhibitors will prevent the production of citrulline. IC50 values for inhibition of recombinant PADs were determined from dose-response curves from 2 trials at each inhibitor concentration in a 7-point dilution series from 0 to 7.5 uM (PADs 1-3) or 0 to 4 uM (PAD4).
Protocol Summary:
Recombinant PAD1 (0.2 uM; Assay 1), PAD2 (0.5 uM; Assay 2), PAD3 (0.5 uM; Assay 3), or PAD4 (0.2 uM; Assay 4) in assay buffer (50 mM NaCl, 10 mM CaCl2, 2 mM DTT, 100 mM Tris-HCl, pH 7.6) was treated with test compound (0-7.5 uM final concentration; stock in DMSO) for 15 minutes at 37 C. Substrate BAEE (10 mM) was added, and the reaction was incubated for 15 minutes at 37 C in 60 uL total reaction volume. The reaction was quenched by flash freezing in liquid nitrogen, and a color-developing reagent for detection of the enzymatic byproduct citrulline (COLDER; 200 uL), which consists of solution A (80 mM diacetyl monoxime and 2 mM thiosemicarbazide) and solution B (3 M H3PO4, 6 M H2SO4, and 2 mM NH4Fe(SO4)2) in a 1:3 ratio, was added. This mixture was incubated for 30 minutes at 95 C and the absorbance was measured at 540 nm. The amount of product produced was determined by comparison to a standard curve with known concentrations of citrulline.
%_Inhibition = 1 - ( ( ABStest - Blank ) / Correction_Factor ) / ( ( ABSDMSO - Blank ) / Correction_Factor)
Where:
ABStest is defined as absorbance at 540 nm for target treated with test compound.
ABSDMSO is defined as absorbance at 540 nm for target treated with DMSO.
Blank is defined as the absorbance of a blank sample at 540 nm.
Correction_Factor is defined as the correction factor generated from a standard curve of known concentrations of citrulline.
The percent activity remaining was fit to the following equation using GraFit (version 5.0.11):
Fractional_Activity = 1 / ( 1 + ( Conc / IC50 ) )
Where:
Conc is the concentration of inhibitor.
IC50 is the concentration of inhibitor that yields half-maximal activity.
PubChem Activity Outcome and Score:
The following applies to each panel in this assay:
Compounds with IC50 values less than or equal to 1 uM were considered active. Compounds with IC50 values less than 1 uM were considered inactive.
Overall Outcome and Score:
The overall outcome was active if the compound was active in at least one panel, inactive otherwise.
The overall score is 0 if the compound was inactive, otherwise the score is taken as the fraction of panels where the compound is active, multiplied by 100.
The PubChem Activity Score range for active compounds is 75-75. There are no inactive compounds.
List of Reagents:
Recombinant PADs 1-4 (supplied by Assay Provider)
Tris HCl (Sigma, part T3038)
CaCl2 (Sigma, part C3881)
DTT (RPI, part D110000)
2,3-butanedione monooxime (Sigma, part B0753)
thiosemicarbazide (Sigma, part T33405)
NH4Fe(SO4)2 (Sigma, part F1668)
H2SO4 (Sigma, part 258105)
H3PO4 (Fisher, part A260)
NaCl (Sigma, part S6546)
BAEE (Sigma, part B4500)
96-well plates (BD Falcon, part 353228)
Comment
This assay was performed by the assay provider with powder compounds.
Categorized Comment - additional comments and annotations
From BioAssay Depositor:
BAO: bioassay specification: assay biosafety level: bsl1
BAO: bioassay specification: assay measurement type: endpoint assay
BAO: bioassay specification: assay readout content: assay readout method: regular screening
BAO: bioassay specification: assay readout content: content readout type: single readout
BAO: bioassay specification: assay stage: secondary: selectivity
BAO: detection technology: spectrophotometry: absorbance
BAO: meta target detail: binding reporter specification: interaction: protein-small molecule
BAO: meta target: molecular target: protein target: enzyme: generic hydrolase
BAO: version: 1.4b1080
From PubChem:
Assay Format: Biochemical
Result Definitions
Show more
TIDNameDescriptionPID§Panel TargetsHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
ScoreThe BioAssay activity ranking scoreInteger
1Outcome [PAD1]One of Active, Inactive, or Not Tested1protein-arginine deiminase type-1 [Homo sapiens]Outcome
2Average IC50 [PAD1]*The average concentration at which 50 percent of the activity in the antagonist assay is observed; (IC50) shown in micromolar.1FloatμM
3Standard Deviation [PAD1]The standard deviation of the IC50 value.1Float
4Inhibition at 0 uM [1] [PAD1] (0μM**)The value for percent inhibition at 0 uM compound.1Float%
5Inhibition at 0.3 uM [1] [PAD1] (0.3μM**)The value for percent inhibition at 0.3 uM compound1Float%
6Inhibition at 0.4 uM [1] [PAD1] (0.4μM**)The value for percent inhibition at 0.4 uM compound.1Float%
7Inhibition at 0.5 uM [1] [PAD1] (0.5μM**)The value for percent inhibition at 0.5 uM compound.1Float%
8Inhibition at 1 uM [1] [PAD1] (1μM**)The value for percent inhibition at 1 uM compound.1Float%
9Inhibition at 5 uM [1] [PAD1] (5μM**)The value for percent inhibition at 5 uM compound.1Float%
10Inhibition at 7.5 uM [1] [PAD1] (7.5μM**)The value for percent inhibition at 7.5 uM compound.1Float%
11Inhibition at 0 uM [2] [PAD1] (0μM**)The value for percent inhibition at 0 uM compound.1Float%
12Inhibition at 0.3 uM [2] [PAD1] (0.3μM**)The value for percent inhibition at 0.3 uM compound1Float%
13Inhibition at 0.4 uM [2] [PAD1] (0.4μM**)The value for percent inhibition at 0.4 uM compound.1Float%
14Inhibition at 0.5 uM [2] [PAD1] (0.5μM**)The value for percent inhibition at 0.5 uM compound.1Float%
15Inhibition at 1 uM [2] [PAD1] (1μM**)The value for percent inhibition at 1 uM compound.1Float%
16Inhibition at 5 uM [2] [PAD1] (5μM**)The value for percent inhibition at 5 uM compound.1Float%
17Inhibition at 7.5 uM [2] [PAD1] (7.5μM**)The value for percent inhibition at 7.5 uM compound.1Float%
18Outcome [PAD2]One of Active, Inactive, or Not Tested2protein-arginine deiminase type-2 [Homo sapiens]Outcome
19Average IC50 [PAD2]*The average concentration at which 50 percent of the activity in the antagonist assay is observed; (IC50) shown in micromolar.2FloatμM
20Standard Deviation [PAD2]The standard deviation of the IC50 value.2Float
21Inhibition at 0 uM [1] [PAD2] (0μM**)The value for percent inhibition at 0 uM compound.2Float%
22Inhibition at 0.3 uM [1] [PAD2] (0.3μM**)The value for percent inhibition at 0.3 uM compound2Float%
23Inhibition at 0.4 uM [1] [PAD2] (0.4μM**)The value for percent inhibition at 0.4 uM compound.2Float%
24Inhibition at 0.5 uM [1] [PAD2] (0.5μM**)The value for percent inhibition at 0.5 uM compound.2Float%
25Inhibition at 1 uM [1] [PAD2] (1μM**)The value for percent inhibition at 1 uM compound.2Float%
26Inhibition at 5 uM [1] [PAD2] (5μM**)The value for percent inhibition at 5 uM compound.2Float%
27Inhibition at 7.5 uM [1] [PAD2] (7.5μM**)The value for percent inhibition at 7.5 uM compound.2Float%
28Inhibition at 0 uM [2] [PAD2] (0μM**)The value for percent inhibition at 0 uM compound.2Float%
29Inhibition at 0.3 uM [2] [PAD2] (0.3μM**)The value for percent inhibition at 0.3 uM compound2Float%
30Inhibition at 0.4 uM [2] [PAD2] (0.4μM**)The value for percent inhibition at 0.4 uM compound.2Float%
31Inhibition at 0.5 uM [2] [PAD2] (0.5μM**)The value for percent inhibition at 0.5 uM compound.2Float%
32Inhibition at 1 uM [2] [PAD2] (1μM**)The value for percent inhibition at 1 uM compound.2Float%
33Inhibition at 5 uM [2] [PAD2] (5μM**)The value for percent inhibition at 5 uM compound.2Float%
34Inhibition at 7.5 uM [2] [PAD2] (7.5μM**)The value for percent inhibition at 7.5 uM compound.2Float%
35Outcome [PAD3]One of Active, Inactive, or Not Tested3protein-arginine deiminase type-3 [Homo sapiens]Outcome
36Average IC50 [PAD3]*The average concentration at which 50 percent of the activity in the antagonist assay is observed; (IC50) shown in micromolar.3FloatμM
37Standard Deviation [PAD3]The standard deviation of the IC50 value.3Float
38Inhibition at 0 uM [1] [PAD3] (0μM**)The value for percent inhibition at 0 uM compound.3Float%
39Inhibition at 0.3 uM [1] [PAD3] (0.3μM**)The value for percent inhibition at 0.3 uM compound3Float%
40Inhibition at 0.4 uM [1] [PAD3] (0.4μM**)The value for percent inhibition at 0.4 uM compound.3Float%
41Inhibition at 0.5 uM [1] [PAD3] (0.5μM**)The value for percent inhibition at 0.5 uM compound.3Float%
42Inhibition at 1 uM [1] [PAD3] (1μM**)The value for percent inhibition at 1 uM compound.3Float%
43Inhibition at 5 uM [1] [PAD3] (5μM**)The value for percent inhibition at 5 uM compound.3Float%
44Inhibition at 7.5 uM [1] [PAD3] (7.5μM**)The value for percent inhibition at 7.5 uM compound.3Float%
45Inhibition at 0 uM [2] [PAD3] (0μM**)The value for percent inhibition at 0 uM compound.3Float%
46Inhibition at 0.3 uM [2] [PAD3] (0.3μM**)The value for percent inhibition at 0.3 uM compound3Float%
47Inhibition at 0.4 uM [2] [PAD3] (0.4μM**)The value for percent inhibition at 0.4 uM compound.3Float%
48Inhibition at 0.5 uM [2] [PAD3] (0.5μM**)The value for percent inhibition at 0.5 uM compound.3Float%
49Inhibition at 1 uM [2] [PAD3] (1μM**)The value for percent inhibition at 1 uM compound.3Float%
50Inhibition at 5 uM [2] [PAD3] (5μM**)The value for percent inhibition at 5 uM compound.3Float%
51Inhibition at 7.5 uM [2] [PAD3] (7.5μM**)The value for percent inhibition at 7.5 uM compound.3Float%
52Outcome [PAD4]One of Active, Inactive, or Not Tested4protein-arginine deiminase type-4 [Homo sapiens]Outcome
53Average IC50 [PAD4]*The average concentration at which 50 percent of the activity in the antagonist assay is observed; (IC50) shown in micromolar.4FloatμM
54Standard Deviation [PAD4]The standard deviation of the IC50 value.4Float
55Inhibition at 0 uM [1] [PAD4] (0μM**)The value for percent inhibition at 0 uM compound.4Float%
56Inhibition at 0.5 uM [1] [PAD4] (0.5μM**)The value for percent inhibition at 0.5 uM compound4Float%
57Inhibition at 0.75 uM [1] [PAD4] (0.75μM**)The value for percent inhibition at 0.75 uM compound.4Float%
58Inhibition at 1 uM [1] [PAD4] (1μM**)The value for percent inhibition at 1 uM compound.4Float%
59Inhibition at 2 uM [1] [PAD4] (2μM**)The value for percent inhibition at 2 uM compound.4Float%
60Inhibition at 2.5 uM [1] [PAD4] (2.5μM**)The value for percent inhibition at 2.5 uM compound.4Float%
61Inhibition at 4 uM [1] [PAD4] (4μM**)The value for percent inhibition at 4 uM compound.4Float%
62Inhibition at 0 uM [2] [PAD4] (0μM**)The value for percent inhibition at 0 uM compound.4Float%
63Inhibition at 0.5 uM [2] [PAD4] (0.5μM**)The value for percent inhibition at 0.5 uM compound4Float%
64Inhibition at 0.75 uM [2] [PAD4] (0.75μM**)The value for percent inhibition at 0.75 uM compound.4Float%
65Inhibition at 1 uM [2] [PAD4] (1μM**)The value for percent inhibition at 1 uM compound.4Float%
66Inhibition at 2 uM [2] [PAD4] (2μM**)The value for percent inhibition at 2 uM compound.4Float%
67Inhibition at 2.5 uM [2] [PAD4] (2.5μM**)The value for percent inhibition at 2.5 uM compound.4Float%
68Inhibition at 4 uM [2] [PAD4] (4μM**)The value for percent inhibition at 4 uM compound.4Float%

* Activity Concentration. ** Test Concentration. § Panel component ID.
Additional Information
Grant Number: R01 GM079357-01

Classification
PageFrom: